VISCERAL FAT FIRST: WHY MEN LOSE BELLY FAT DIFFERENTLY ON GLP-1S

Updated July 18, 2026

Men store fat differently than women — and GLP-1 medications appear to target that difference in ways that disproportionately benefit men. Specifically, GLP-1s reduce visceral fat (the metabolically active fat packed around your organs) at a faster rate than subcutaneous fat (the fat under your skin that you can pinch). For men, who carry more visceral fat than women, this is among the most clinically significant effects of treatment.

WHY MEN CARRY MORE VISCERAL FAT

Testosterone and estrogen determine where your body preferentially stores fat. Testosterone directs fat storage toward the visceral compartment (around the liver, intestines, and kidneys — the "beer belly"). Estrogen directs fat storage subcutaneously (under the skin, in the hips, thighs, and arms).

This is why men develop central obesity (the apple shape) while women develop peripheral obesity (the pear shape). A man at 30% body fat may have 20 to 30% of his total fat stored viscerally. A woman at 30% body fat typically has 10 to 15% stored viscerally. Same total fat, radically different metabolic risk profile.

Visceral fat is not just ugly — it is biologically dangerous. It secretes inflammatory cytokines (IL-6, TNF-α), produces excess estrogen through aromatase activity, and directly contributes to insulin resistance, fatty liver disease, and cardiovascular risk. For men, reducing visceral fat is arguably more important than reducing total body weight.

HOW GLP-1s TARGET VISCERAL FAT

GLP-1 receptor agonists appear to preferentially reduce visceral fat through several mechanisms:

Direct hepatic effects. GLP-1 receptors are expressed in the liver. Semaglutide and tirzepatide reduce hepatic fat content (liver fat) by 40 to 70% in clinical studies — a dramatically larger reduction than overall body fat percentage change. Since liver fat is a component of visceral fat, this drives disproportionate visceral fat loss.

Improved insulin sensitivity. Visceral fat is both a cause and consequence of insulin resistance. GLP-1s improve insulin signaling, which allows the body to mobilize visceral fat stores more efficiently than subcutaneous fat. This creates a preferential depletion of the visceral compartment.

Reduced inflammatory signaling. GLP-1 medications reduce systemic inflammation (measured by CRP and other markers), which downregulates the inflammatory cycle that maintains visceral fat deposits. Subcutaneous fat does not participate in this inflammatory cycle to the same degree.

The practical result: men on GLP-1 medications often see their waist circumference decrease faster than their overall weight. A man who loses 20 pounds in 3 months may see his waist drop by 3 to 4 inches — a disproportionate reduction that reflects preferential visceral fat loss.

TRACKING IT: WAIST CIRCUMFERENCE IS YOUR BEST FRIEND

The simplest, cheapest, and most informative measurement during GLP-1 treatment is waist circumference at the navel. Measure it once per week, same time (morning, before eating), same conditions (standing, relaxed belly, exhale and measure).

Why this matters more than the scale: a man who loses 3 inches off his waist but only 10 pounds on the scale has lost significant visceral fat while potentially preserving muscle. The scale says "modest progress." The tape measure says "your metabolic risk just dropped substantially."

Clinical thresholds: below 40 inches is the general health target. Below 37 inches is where most cardiovascular risk markers normalize. Below 34 inches is lean. Track your trajectory — the rate of waist reduction often outpaces weight loss in the first 3 months of GLP-1 treatment.

Sources: STEP trial body composition data; visceral fat and GLP-1 receptor signaling research; hepatic fat reduction data from semaglutide and tirzepatide Phase III trials; sex differences in body fat distribution literature. This article does not constitute medical advice.